115 filings
Page 5 of 6
8-K
va2qcvl6
29 May 19
Submission of Matters to a Vote of Security Holders
5:05pm
8-K
8l2b mion
22 May 19
Regulation FD Disclosure
6:10am
8-K
xq4s9z2g18 snbse1ps
20 May 19
Entry into a Material Definitive Agreement
9:28am
8-K
gsf y028dadmb9xwz05
20 May 19
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
9:04am
8-K
leglew5sw
7 May 19
BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update
8:17am
8-K
2959gpsn 3q80vaf
1 Apr 19
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
4:08pm
8-K
zpq5z
25 Mar 19
Other Events
4:45pm
8-K
d7hkara5 xa74
12 Mar 19
Other Events
5:21pm
8-K
mnhi8m0dt lotklu4
11 Mar 19
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
4:38pm
8-K
e0446p2fx yncsj
7 Mar 19
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update
4:42pm
8-K
u6pih34
4 Mar 19
Other Events
4:19pm
8-K
0jw9l 6rhnzm771ltivf
11 Feb 19
Regulation FD Disclosure
4:47pm
8-K
rcbwfpk
4 Feb 19
Other Events
5:03pm
8-K
5ggky1tvmgsg e0q8
3 Jan 19
Regulation FD Disclosure
4:16pm
8-K
cjd9bhvv6 g8219v
27 Dec 18
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation
4:11pm
8-K
ukcqyr
20 Dec 18
BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation
5:08pm
8-K
juk9eh6qi5o odvqnf6z
12 Dec 18
Regulation FD Disclosure
4:11pm
8-K
bt36qubfuaqomfilw
12 Dec 18
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead
9:05am
8-K
2qqqs
14 Nov 18
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia PatientsĀ Supporting BXCL501 Clinical Development
8:44am
8-K
utua0 7p7qf
9 Nov 18
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
7:35am